BYSI unit SEED Therapeutics gets FDA orphan drug designation for ST-01156
BeyondSpring’s subsidiary SEED Therapeutics receives FDA orphan drug designation for ST-01156, a small molecule degrader of RNA-binding motif protein 39, for neuroblastoma.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.